The Conundrum of Switching DAPT

The Conundrum of Switching DAPT - TCTMD.com

The Conundrum of Switching DAPT. Presenter: Dean Kereiakes. October 31, 2013. REGISTER for free or LOG IN to view this content. The Conundrum of Switching ...

International Expert Consensus on Switching Platelet P2Y 12 ...

Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor is the treatment of choice for the prevention of atherothrombotic events in ...

Switching P2Y12-receptor inhibitors in patients with coronary artery ...

Dual antiplatelet therapy--the combination of aspirin and a P2Y12-receptor inhibitor--is the cornerstone of treatment of patients with acute coronary ...

The Conundrum of Anticoagulation and Antiplatelet Therapy in ...

Current consensus is to stop anticoagulation once SCAD has been diagnosed and start dual antiplatelet therapy (DAPT) for 30 days followed by 1 ...

International Expert Consensus on Switching Platelet P2Y

The availability of different oral. P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) has enabled physicians to contemplate switching among ...

The conundrum of simultaneous antiplatelet and anticoagulant therapy

Antiplatelet therapy is the cornerstone of secondary prevention of coronary artery disease, and dual antiplatelet therapy (DAPT) has become the standard of ...

ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy

A patient with CAD may require DAPT in the context of myocardial revascularization (e.g., percutaneous coronary intervention [PCI] or coronary artery bypass ...

Short dual antiplatelet therapy and dual antiplatelet therapy de ...

Switching to ticagrelor monotherapy after 3 months of DAPT significantly ... Genotyping: one piece of the puzzle to personalize antiplatelet therapy. J ...

Antiplatelet therapy after percutaneous coronary intervention

In patients undergoing PCI, the association of aspirin plus a P2Y12 inhibitor, a strategy known as dual antiplatelet therapy (DAPT), has represented the ...

De-Escalation of P2Y12-Inhibiting Therapies to Reduce the Risk of ...

Dual antiplatelet therapy (DAPT) with aspirin and an oral P2Y12 receptor inhibitor (clopidogrel, prasugrel, or ticagrelor) is the cornerstone of ...

Shortening Dual Antiplatelet Therapy Duration in High-Risk Patients ...

Patients at high bleeding risk (HBR) may benefit from changing or adjusting either the components or the duration of DAPT. Shortening DAPT ...

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After ...

All BARC bleeding as well as TIMI minor bleeding also favored the patients whose DAPT regimen was switched to clopidogrel, while TIMI major ...

Antiplatelet therapy – a summary for the general physicians

Switching between P2Y12 inhibitors. Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor is standard after acute coronary syndromes, with either medical ...

The Conundrum Surrounding Racial Differences on Ischaemic and ...

shifting the focus from the optimal duration of DAPT to the ischaemia/bleeding risk trade-off of DAPT continuation. However, there are some ...

Antithrombotic Therapy in AF-PCI Patients | ICR Journal

... DAPT modulation strategies (i.e. shortening DAPT duration and switching to lower-potency regimens).34. Evidence at a Glance. The latest ...

The management of antiplatelet therapy in acute coronary syndrome ...

Dual antiplatelet therapy (DAPT) consisting of aspirin and a P2Y12 receptor antagonist is a fundamental component of acute coronary syndrome (ACS) manageme.

The conundrum of percutaneous coronary intervention without aspirin

(DAPT). Despite this, aspirin remains deeply engrained in clinical practice ... There is no way to change clinical practice without a well-designed randomised.

Single antiplatelet therapy directly after percutaneous coronary ...

However, all these trials included at least 1 to 3 months of DAPT before switching to P2Y12 inhibitor monotherapy, whereas the average daily bleeding risk is ...

Switching P2Y12-receptor inhibitors in patients with coronary artery ...

Abstract. Dual antiplatelet therapy--the combination of aspirin and a P2Y12 -receptor inhibitor--is the cornerstone of treatment of patients with acute coronary ...

[PDF] ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy

The patientlevel landmark meta-analysis by Kang et al is a meaningful asset to understand whether racial differences truly exist in the net benefit of DAPT, ...